MedImmune, Inc. | Home Page

MedImmune to Present at Lazard's Annual Life Sciences Conference More...
MedImmune and Medarex Announce Collaboration to Develop and Commercialize Fully Human Antibodies for Autoimmune Diseases More...
MedImmune Initiates Phase 3 Study for Numax(TM) in Native American Infants More...
MedImmune Appoints New Vice President, Medical Affairs More...
MedImmune to Present at the CSFB Annual Healthcare Conference More...
MedImmune to Present at CIBC World Markets Fifteenth Annual Healthcare Conference More...
MedImmune Initiates Pivotal Phase 3 Study for Numax(TM) to Prevent Respiratory Syncytial Virus in High-Risk Infants More...
Medimmune Completes Enrollment in Phase 3 Study Comparing Next-Generation, Intranasal Influenza Vaccine to Injectable Influenza Vaccine More...
CDC Advisory Committee Votes to Include FluMist(R) in the Vaccines for Children Program for 2005-2006 Influenza Season More...
MedImmune Expands Production Plans For FluMist(R) More...
MedImmune Reports Record Revenues for First Nine Months of 2004 More...
MedImmune Initiates Phase 3 Clinical Trial Comparing Intranasal Influenza Vaccine With Injectable Flu Vaccine More...
MedImmune Promotes Edward Connor, M.D., to Executive Vice President & Chief Medical Officer and Appoints New Senior Executives More...
MedImmune Progressing with Development of Vaccine Targeting Respiratory Syncytial Virus and Parainfluenza Virus Type-3 More...
MedImmune Named One of Maryland's Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program More...
FluMist(R) Now Available for the 2004-2005 Flu Season More...
MedImmune to Announce 2004 Third Quarter Financial Results on October 21, 2004 More...
MedImmune to Present at 2004 UBS Global Life Sciences Conference More...
MedImmune to Present at Bear Stearns 17th Annual Healthcare Conference More...
MedImmune to Present at Thomas Weisel Partners Healthcare Tailwinds 2004 More...
MedImmune Discontinues Rheumatoid Arthritis and Psoriasis Trials for Vitaxin(R) More...
MedImmune Begins Phase 1 Clinical Trial for Its Anti-Interleukin-9 Monoclonal Antibody More...
MedImmune's Newly Identified EphA2 Protein May Signal Progression of Ovarian Cancer More...
FDA Approves Liquid Formulation of Synagis(R) More...
MedImmune Reports 2004 Second Quarter and Six-Month Results More...
MedImmune's New R&D; Facility and Corporate Headquarters Named 'Best Biotech Office' More...
MedImmune Selects Henry Schein as Exclusive Distributor of FluMist(TM) More...
Data Show Ethyol(R) Reduces Radiation Therapy-Induced Dry Mouth in Head and Neck Cancer Patients For 24 Months More...
PATRICIA : Trial Launched of New Vaccine Aimed at Preventing Cervical Cancer (release issued May 19 by GlaxoSmithKline) More...
Intranasal Influenza Vaccine Shows Higher Efficacy Rate Compared to Traditional Flu Shot More...
MedImmune and Cerus Enter Agreement to Co-Develop Therapeutic Vaccine For Cancer More...
MedImmune Appoints CFO, Promotes Several Senior Executives More...
MedImmune Implements Plan to Achieve $2 Billion In Revenues By 2009 More...
MedImmune Identifies Novel Protein Target for Cancer Therapy More...
MedImmune Demonstrates Proof of Principle for Targeting EphA2 Protein Overexpressed on Cancer Cells More...
MedImmune Files Numax(TM) Investigational New Drug Application More...

Oct	DEC	Jan
	04
2003	2004	2005